Business Wire

HOF Capital Completes €1 Billion Acquisition of Porsche’s Stakes in Bugatti Rimac and Rimac Group

9.9.2026 19:00:00 EEST | Business Wire | Press release

Share

HOF Capital today announced the completion of its acquisition of Porsche’s equity interests in Bugatti Rimac and Rimac Group through an HOF-led consortium. The transaction, first announced in April 2026, closed following the satisfaction of all conditions, including regulatory clearances. Porsche’s combined interests were valued at approximately €1 billion.

HOF Capital originated and led the transaction, assembling a consortium of institutional investors from the United States and Europe. Following completion of the transaction, HOF holds a 23.5% stake and becomes the largest shareholder in Rimac Group, which holds the 55% controlling interest in Bugatti Rimac. HOF and its consortium also acquired Porsche’s direct 45% interest in Bugatti Rimac.

As part of the investment, HOF Capital holds three supervisory board seats across Rimac Group and Bugatti Rimac. Hisham Elhaddad, Co-Founder and Managing Partner of HOF Capital, has joined the Supervisory Boards of both Bugatti Rimac and Rimac Group. Josh Klaczek, Partner at HOF Capital, joins the Rimac Group Supervisory Board as the firm’s second representative.

Hisham Elhaddad, Co-Founder and Managing Partner of HOF Capital commented: “This transaction reflects exactly the kind of partnership HOF was built for – backing durable, category-defining businesses across industries. Bugatti’s position at the apex of personal luxury and bespoke craftsmanship is especially compelling as we enter an era defined by abundance. We are excited to be partnering with a world-class leader in Mate Rimac and his exceptional team to enhance the value of this iconic brand. For HOF, this deal marks a natural extension of our venture roots into leading complex transactions across the capital structure.”

Mate Rimac, CEO of Bugatti Rimac: “This is an important step for Bugatti Rimac and the entire Rimac Group. I am delighted that HOF Capital and its consortium are becoming our partners in the next phase of our Group's development, and I look forward to working together to realize the full potential of our companies. We have made strong progress across all companies in the Group, and I believe this partnership gives additional momentum to our continued growth.”

ABOUT BUGATTI

Founded in 1909 by Ettore Bugatti in Molsheim, France, Bugatti is one of the world’s most exclusive automotive marques — synonymous with a singular blend of artistry, craftsmanship, and engineering excellence. Since 2021, the brand has operated as part of Bugatti Rimac, led by Chief Executive Officer Mate Rimac. Bugatti’s latest flagship, the Tourbillon, marks the beginning of a new chapter for the marque. Bugatti remains headquartered at its historic home in Molsheim, with additional operations in Zagreb, Croatia.

ABOUT RIMAC GROUP

Rimac Group is the majority shareholder of Bugatti Rimac, the sole owner of Rimac Technology and Rimac Energy, and a significant minority investor in Verne. Rimac Group companies employ over 2,000 employees, develop and produce Bugatti and Rimac branded hypercars as well as battery systems, powertrain systems, electronics, and stationary storage systems. Rimac’s headquarters is based on the outskirts of Zagreb, Croatia, with additional locations across Europe.

ABOUT HOF CAPITAL

HOF Capital is a New York-based investment firm with approximately $15 billion in AUM. The firm invests globally across venture capital and growth equity, partnering with companies from first check through IPO. HOF has backed several of today’s most consequential companies early on, including Anthropic and SpaceX, and invests thematically across AI, frontier technologies, critical infrastructure, and iconic brands. Its investor base spans Fortune 500 enterprises, financial institutions, and industry-leading founders worldwide. For more information, visit hofcapital.com.

This press release is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security or investment product, and shall not form the basis of or be relied on in connection with any investment decision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909929325/en/

Contacts

MEDIA CONTACT
Prosek Partners
pro-HofCapital@prosek.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye